Chlorzoxazone reduced the paracetamol-induced toxicity via competitive inhibition of CYP2E1-mediated metabolism

被引:1
|
作者
Pingili, Ravindra Babu [1 ]
Vemulapalli, Sridhar [2 ,3 ]
Gadamsetty, Manideep V. V. N. [3 ]
Presingu, Divya [3 ]
Katuri, Ruthvik [3 ]
Rachamsetty, Vijayalakshmi [3 ]
Kilaru, Naveen Babu [3 ]
机构
[1] SVKMs NMIMS, Sch Pharm & Technol Management, Shirpur 425405, Maharashtra, India
[2] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA
[3] KVSR Siddhartha Coll Pharmaceut Sci, Dept Pharmaceut & Pharmaceut Biotechnol, Vijayawada 520010, Andhra Pradesh, India
关键词
N-Acetyl-p-benzoquinoneimine; Chlorzoxazone; Paracetamol; Hepatotoxicity; Nephrotoxicity; INDUCED LIVER-INJURY; P-GLYCOPROTEIN; CYTOCHROME P4502E1; WISTAR RATS; IN-VITRO; ACETAMINOPHEN HEPATOTOXICITY; PHARMACOKINETIC INTERACTION; ETHANOL; CYP2E1; COMBINATION;
D O I
10.1186/s43094-023-00484-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundDrug metabolism is crucial to attaining the therapeutic index of any drug. The metabolism and elimination of the drugs are governed mainly by P-glycoprotein (P-gp) and Cytochrome P450 (CYP). Paracetamol is mostly used as analgesic and antipyretic agent. The metabolism of paracetamol is primarily via Glucuronidation and sulphation at therapeutic doses. About 5-10% of paracetamol is metabolized via CYP mediated pathway. Cytochrome P450 2E1 (CYP2E1) is primarily responsible for forming a toxic metabolite of paracetamol called N-acetyl-p-benzoquinoneimine (NAPQI). Even at therapeutic doses, long-term usage of paracetamol leads to the hepatic and nephrotoxicity because of NAPQI. Several in-vitro and in-vivo studies conducted by different research groups and reported that chlorzoxazone is a substrate and inhibitor of CYP2E1. However, the effect of chlorzoxazone on the paracetamol (CYP2E1 substrate) metabolism via the CYP2E1 has not yet been reported. This study investigated the effect of chlorzoxazone on the CYP2E1-mediated metabolism of Paracetamol and NAPQI formation in Wistar rats.ResultsFor 15 days, animals were orally administered with Paracetamol (300 mg/kg) with and without Silymarin (100 mg/kg) (standard CYP2E1 inhibitor) and Chlorzoxazone (50 and 100 mg/kg). Analysis was performed using RP-HPLC on the 15th day to determine paracetamol and NAPQI concentration in the plasma. Paracetamol combination with chlorzoxazone (50 and 100 mg/kg) showed a dose-dependent increase in the AUC(0-infinity) and the peak plasma concentration (C-max) of Paracetamol and a dose-dependent decrease of AUC(0-infinity) and C-max of NAPQI compared to paracetamol control (p < 0.001). Chlorzoxazone significantly decreased the elevated liver and renal markers compared to paracetamol control. Simultaneously, Hepatic and nephrotic tissue studies showed that compared to the paracetamol control group, the combination of chlorzoxazone significantly ameliorated paracetamol-induced hepatotoxicity and nephrotoxicity.ConclusionFinally, this study revealed that paracetamol in combination with chlorzoxazone led to a significant decrease in the plasma levels of NAPQI and enhanced absorption of paracetamol in rats via the inhibition of CYP2E1- mediated metabolism. In addition, chlorzoxazone significantly ameliorated paracetamol-induced hepatotoxicity and nephrotoxicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Inhibition of urethane-induced carcinogenicity in Cyp2e1-/- in comparison to Cyp2e1+/+ mice
    Ghanayem, Burhan I.
    TOXICOLOGICAL SCIENCES, 2007, 95 (02) : 331 - 339
  • [42] Apigenin protects against alcohol-induced liver injury in mice by regulating hepatic CYP2E1-mediated oxidative stress and PPARα-mediated lipogenic gene expression
    Wang, Feng
    Liu, Jin-Cheng
    Zhou, Rui-Jun
    Zhao, Xi
    Liu, Mei
    Ye, Hua
    Xie, Mei-Lin
    CHEMICO-BIOLOGICAL INTERACTIONS, 2017, 275 : 171 - 177
  • [43] SINGLE-DOSE DISULFIRAM INHIBITION OF CHLORZOXAZONE METABOLISM - A CLINICAL PROBE FOR P450-2E1
    KHARASCH, ED
    THUMMEL, KE
    MHYRE, J
    LILLIBRIDGE, JH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) : 643 - 650
  • [44] Therapeutic hypothermia-induced pharmacokinetic alterations on CYP2EI chlorzoxazone-mediated metabolism in a cardiac arrest rat model
    Tortorici, MA
    Kochanek, PM
    Bies, RR
    Poloyac, SM
    CRITICAL CARE MEDICINE, 2006, 34 (03) : 785 - 791
  • [45] CYP2E1-dependent benzene toxicity: the role of extrahepatic benzene metabolism
    Ulrike Bernauer
    Bärbel Vieth
    Rainer Ellrich
    Barbara Heinrich-Hirsch
    Gerd-Rüdiger Jänig
    Ursula Gundert-Remy
    Archives of Toxicology, 1999, 73 : 189 - 196
  • [46] CYP2E1-dependent benzene toxicity:: the role of extrahepatic benzene metabolism
    Bernauer, U
    Vieth, B
    Ellrich, R
    Heinrich-Hirsch, B
    Jänig, GR
    Gundert-Remy, U
    ARCHIVES OF TOXICOLOGY, 1999, 73 (4-5) : 189 - 196
  • [47] Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression
    Valentine, JL
    Lee, SST
    Seaton, MJ
    Asgharian, B
    Farris, G
    Corton, JC
    Gonzalez, FJ
    Medinsky, MA
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1996, 141 (01) : 205 - 213
  • [48] CYP2E1 in 1,4-dioxane metabolism and liver toxicity: insights from CYP2E1 knockout mice study
    Wang, Yewei
    Charkoftaki, Georgia
    Orlicky, David J.
    Davidson, Emily
    Aalizadeh, Reza
    Sun, Ning
    Ginsberg, Gary
    Thompson, David C.
    Vasiliou, Vasilis
    Chen, Ying
    ARCHIVES OF TOXICOLOGY, 2024, 98 (10) : 3241 - 3257
  • [49] Caralluma umbellata Haw. protects liver against paracetamol toxicity and inhibits CYP2E1
    Bellamakondi, Pavan Kumar
    Godavarthi, Ashok
    Ibrahim, Mohammed
    BIOIMPACTS, 2018, 8 (01) : 23 - 30
  • [50] TRPV4 regulates inflammation and Kupffer cell activation in nonalcoholic steatohepatitis by attenuation of CYP2E1-mediated oxidative stress
    Seth, Ratanesh K.
    Das, Suvarthi
    Dattaroy, Diptadip
    Alhasson, Firas
    Bell, Phillip D.
    Michelotti, Gregory A.
    Nagarkatti, Mitzi
    Nagarkatti, Prakash
    Liedtke, Wolfgang B.
    Diehl, Anna Mae
    Chatterjee, Saurabh
    HEPATOLOGY, 2015, 62 : 1248A - 1248A